Treatment of acute immune TTP is with both:
Early administration of rituximab during acute episodes reduces time to remission and rituximab should be started within 72 hours of diagnosis. On average, inpatient stay is 14 days and treatment continues as an outpatient, aiming to normalise ADAMTS13 activity (1)
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.